EGFR and non-small cell lung carcinoma: Given the increasing interest in applying immunotherapy in combination with targeted therapies to try and circumvent this issue and increase efficacy of ICB in EGFR-driven NSCLC, different efforts have been made to investigate combination therapy regimes [13,14,15].